Edwards Lifesciences Corporation entered into an Amended and Restated Five Year Credit Agreement on November 19, 2026. The agreement amends and restates the company’s previous credit facility, which was established on July 15, 2022.
The new agreement provides for a five-year, $750 million multi-currency unsecured revolving credit facility. The facility matures on November 19, 2031. Bank of America, N.A., serves as the Administrative Agent for the facility.
Interest on borrowings denominated in United States dollars is determined by the Secured Overnight Financing Rate (SOFR) or the base rate, at the company’s election. The applicable margin is based on the company’s leverage ratio or debt ratings.
Subject to lender approval, the company may increase the total amount available under the facility by an additional $375 million. The agreement includes customary terms, such as limitations on liens, debt incurrence, mergers, and significant asset dispositions. It also requires the company to maintain a maximum leverage ratio. The company expects to use borrowings from the facility for general corporate purposes. As of the filing date, no amounts have been borrowed under the agreement.